Exco InTouch Successfully Completes HIPAA Security Audit
Exco InTouch announced the successful completion of an independent audit
Exco InTouch announced the successful completion of an independent audit assessing compliance utilizing the National Institute of Standards and Technology guidelines for Health Insurance Portability and Accountability Act (HIPAA) security.
Of the 64 HIPPA citations the company was audited on, no findings were reported, according the Tim Davis, CEO and co-founder of Exco InTouch.
You can read the full release here.
Semaglutide Significantly Improves Steatohepatitis, Fibrosis in Phase III MASH Trial
May 2nd 2025Interim results from the Phase III ESSENCE trial published in The New England Journal of Medicine show once-weekly semaglutide improved liver histology, metabolic markers, and weight loss in patients with biopsy-confirmed metabolic dysfunction–associated steatohepatitis and stage 2 or 3 fibrosis.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
